Skip to content

TMCT04 - A RANDOMIZED CONTROLLED TRIAL OF URINE CXCL10 CHEMOKINE MONITORING POST-RENAL TRANSPLANT

Kidney Transplant

The study will use a new screening test for rejection of transplanted kidney using urine CXCL10 testing.

In the first year after kidney transplant, the patient will have urine CXCL10 measured at their routine clinic visits. This test will be used to see if the patient is at risk of rejection of transplanted kidney.

If a patient is at risk of rejection, they may be “randomized” (like flipping a coin, heads or tails) to get a kidney transplant biopsy to check for rejection. Early diagnosis and treatment of rejection may help the kidney transplant stay healthy and last longer.

null

Conditions de participation

  • Sexe:

    Male, Female, Intersex

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:
Any new adult kidney transplant patient may be considered. The study coordinator will review your medical history to see if you qualify for this study. Participation is completely voluntary. Your medical care will stay the same, even if you do not participate.
Exclusion Criteria:
Participants who are not eligible for this study:
Individuals meeting any of the following criteria will be excluded from participation:
1. Primary non-function;
2. ABO incompatible with exception of ABO light
3. Pre-transplant donor specific antibody (DSA) positive* (MFI>1000 OR positive flow cross-match);
4. HLA 0 DR + 0 DQ mis-match;
5. Presence of other transplanted organ or co-transplanted organ and/or previous bone marrow or stem cell transplant;
6. Followed outside of investigational center;
7. Participation in other interventional trials with other trial interventions occurring within 4 weeks prior to transplant or anytime post-transplant until study end at 12-months;
8. Intention not to use a maintenance immunosuppression regimen consisting of CNI and anti-proliferative agents;
9. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant’s ability to comply with study requirements or that may impact the quality or interpretation of the data. (ie. COVID-19 positive diagnosis at the time of enrolment)

Lieu de l'étude

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Étude parrainée par
University of Calgary
Participants recherchés
Plus d'informations
ID de l'étude: REB21-0702